Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation

Bone Marrow Transplantation

Volumn 19, Issue 4, 1997, Pages 337-342

  Gertz, M A ^a   Witzig, T E ^a   Pineda, A A ^a   Greipp, P R ^a   Kyle, R A ^a   Litzow, M R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Circulating tumor cells; Multiple myeloma; Peripheral blood stem cell transplantation

Indexed keywords

BETA 2 MICROGLOBULIN;

ADULT; ARTICLE; CANCER SURVIVAL; CELL STRUCTURE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; LABELING INDEX; LEUKAPHERESIS; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL; PLASMA CELL; PRIORITY JOURNAL; STAINING; STEM CELL TRANSPLANTATION; TIME; TREATMENT PLANNING; TUMOR CELL;

EID: 0031050038     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700670     Document Type: Article

References (43)

1. Santos GW. The role of autologous hematopoietic stem cell transplantation in hematologic malignancy (editorial). Curr Opin Oncol 1994; 6: 115-121.
2. Attal M, Harousseau JL, Stoppa AM et al. High dose therapy in multiple myeloma: final analysis of a prospective randomized study of the Intergroupe Français du Myelome (IFM 90). Blood 1995; 86 (Suppl. 1): 124a (Abstr.).
3. Barlogie B, Jagannath S, Vesole D, Tricot G. Hematopoietic stem cell autografts in support of myeloablative therapy for multiple myeloma. J Hematother 1994; 3: 149-153.
4. Alexanian R, Dimopoulos MA, Hester J et al. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278-4282.
5. Cunningham D, Paz-Ares L, Milan S et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759-763.
6. Healy LE, Nirsimloo N, Scott M et al. In vitro proliferation by cells mobilized into the peripheral blood for collection and autologous transplantation. Exp Hematol 1994; 22: 1278-1282.
7. Croockewit S, Raymakers R, Trilsbeek C et al. Primitive multilineage progenitor cells predominate in peripheral blood early after mobilization with high-dose cyclophosphamide and GM-CSF or G-CSF. Leukemia 1994; 8: 2194-2199.
8. Tribalto M, Papa G, Coppetelli U et al. Treatment of multiple myeloma with autologous blood stem cell transplantation. Preliminary results of an Italian multicentric pilot study, Int J Artif Organs 1993; 16 (Suppl. 5): 51-56.
9. Gianni AM, Tarella C, Bregni M et al. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol 1994; 12: 503-509.
10. Cassel A, Leibovitz N, Hornstein L et al. Evidence for the existence of circulating monoclonal B-lymphocytes in multiple myeloma patients. Exp Hematol 1990; 18: 1171-1173.
11. Tienhaara A, Pelliniemi TT. Flow cytometric DNA analysis and clinical correlations in multiple myeloma. Am J Clin Pathol 1992; 97: 322-330.
12. Chen J, Woodliff J, Epstein J. CDRIII analysis helps identify circulating myeloma cell precursors. Proc Ann Meet Am Assoc Cancer Res 1994; 35: 238 (Abstr.).
13. + cells in myeloma patients are tumor cell progenitors. Proc Ann Meet Am Assoc Cancer Res 1992; 33: 229 (Abstr.).
14. Witzig TE, Gertz MA, Pineda AA et al. Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma. Br J Haematol 1995; 89: 640-642.
15. Witzig TE, Dhodapkar MV, Kyle RA, Greipp PR. Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 1993; 72: 108-113.
16. Billadeau D, Van Ness B, Kimlinger T et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 1996; 88: 289-296.
17. Witzig TE, Kimlinger TK, Ahmann GJ et al. Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry 1996; 26: 113-120.
18. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. John Wiley: New York, 1980.
19. Cox DR, Oakes D. Analysis of Survival Data. Chapman and Hall: New York, 1984.
20. Billadeau D, Quam L, Thomas W et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80: 1818-1824.
21. Knauf WU, Pochanke G, Ho AD. Detection of circulating monoclonal lymphocytes in multiple myeloma patients by analysis of gene rearrangements: correlation with progressive disease. Leukemia Res 1993; 17: 341-345.
22. Corradini P, Voena C, Omede P et al. Detection of circulating tumor cells in multiple myeloma by a PCR-based method. Leukemia 1993; 7: 1879-1882.
23. Zandecki M, Facon T, Preudhomme C et al. Significance of circulating plasma cells in multiple myeloma. Leuk Lymphoma 1994; 14: 491-196.
24. Witzig TE, Gertz MA, Lust JA et al. Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: when is the optimal time for stem cell harvest? Leuk Lymphoma 1995; 19: 417-422.
25. Bird JM, Bloxham D, Samson D et al. Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol 1994; 88: 110-116.
26. Craig JI, Langlands K, Parker AC, Anthony RS. Molecular detection of tumor contamination in peripheral blood stem cell harvests. Exp Hematol 1994; 22: 898-902.
27. Mariette X, Fermand JP, Brouet JC. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. Bone Marrow Transplant 1994; 14: 47-50.
28. Vora AJ, Toh CH, Peel J, Greaves M. Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. Br J Haematol 1994; 86: 180-182.
29. de la Rubia J, Bonanad S, Palau J et al. Rapid progression of multiple myeloma following G-CSF mobilization. Bone Marrow Transplant 1994; 14: 475-176.
30. Corradini P, Voena C, Astolfi M et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995; 85: 1596-1602.
31. Dreyfus F, Ribrag V, Leblond V et al. Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 1995; 15: 707-711.
32. Jagannath S, Vesole DH, Tricot G et al. Hemopoietic stem cell transplants for multiple myeloma. Oncology 1994; 8: 89-103.
33. O'Shaughnessy JA, Cowan KH, Cottler-Fox M et al. Autologous transplantation of retrovirally marked CD34-positive bone marrow and peripheral blood cells in patients with multiple myeloma or breast cancer. Prog/Proc Am Soc Clin Oncol 1994; 13: 296 (Abstr.).
34. Björkstrand B, Gahrton G, Dilber MS et al. Retroviral-mediated gene transfer of CD34-enriched bone marrow and peripheral blood cells during autologous stem cell transplantation for multiple myeloma. Hum Gene Ther 1994; 5: 1279-1286.
35. Rill DR, Moen RC, Buschle M et al. An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer. Blood 1992; 79: 2694-2700.
36. Deisseroth AB, Zu Z, Claxton D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous hone marrow in CML. Blood 1994; 83: 3068-3076.
37. Gazitt Y, Tian E, Barlogie B et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1996; 87: 805-811.
38. Lamy T, Drenou B, Grulois I et al. Improvement of hematologic recovery after high-dose intensification using peripheral blood progenitor cells (PBPC) mobilized by chemotherapy and GM-CSF. Ann Hematol 1994; 69: 297-302.
39. Feremans W, Le Moine F, Ravoet C et al. Optimal blood stem cell mobilization using 10 μg/kg granulocyte colony-stimulating factor (G-CSF) alone for high-dose melphalan intensification in multiple myeloma: an intrapatient controlled study. Am J Hematol 1994; 47: 135-138.
40. Celsing F, Hast R, Stenke L et al. Extramedullary progression of multiple myeloma following GM-CSF treatment - grounds for caution? Eur J Haematol 1992; 49: 108 (letter).
41. Boiron JM, Portier M, Lu ZY et al. G-CSF stimulates myeloma cell proliferation in vitro and in vivo through an IL-6 related mechanism. Blood 1991; 78 (Suppl): 385a (Abstr.).
42. Boiron JM, Marit G, Faberes C et al. Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Bone Marrow Transplant 1993; 12: 49-55.
43. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.